

Atlanta Business Chronicle - October 9, 2007
<http://atlanta.bizjournals.com/atlanta/stories/2007/10/08/daily9.html>



Tuesday, October 9, 2007 - 8:55 AM EDT

Metastatix gets new cash boost

Atlanta Business Chronicle

An emerging Atlanta pharmaceutical company has landed \$35 million in series B financing led by **Frazier Healthcare Ventures**.

Frazier Healthcare Ventures General Partner James N. Topper will now join the Metastatix board of directors.

Existing Metastatix investors who also participated in the round of funding included **H.I.G. Ventures, The Aurora Funds, CM Capital, SR One, MedImmune Ventures, Georgia Venture Partners, Centrosome Ventures** and the state of Georgia.

Metastatix Inc. said the new round of funding will be used to conduct clinical trials of MSX-122 in cancer patients and to advance development programs in inflammation and HIV infection. Using technology licensed from Atlanta's Emory University, Metastatix said it is creating a portfolio of chemical compounds that block the CXCR4 receptor. These compounds have shown efficacy in validated pre-clinical models of cancer, inflammation, and T-tropic HIV infection.

All contents of this site © American City Business Journals Inc. All rights reserved.